Cathie Woods's Ark sells more than 100k shares of Exact Sciences (EXAS, $63.70)
Cathie Wood, chief executive of Ark Investment Management, unloaded 175,491 shares of Exact Sciences on Jan. 23, possibly to take advantage of the stock’s recent gains. Exact Sciences is the largest holding in Wood’s flagship Ark Innovation ETF.
Exact Sciences, a medical diagnostics company, has lost 11% in its stock price over the past year, but has climbed +119% since Oct. 14 on the back of strong earnings and the overall market rally.
This unloading comes a few weeks after Wood’s team predicted that Exact Sciences stock could nearly triple in value by the year 2027. On Jan. 5, Ark Invest said, “In our base case, shares of Exact Sciences could compound at an average annual rate of 25%, reaching $140 by 2027.”
EXAS in -0.19% downward trend, sliding for three consecutive days on February 26, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where EXAS declined for three days, in of 344 cases, the price declined further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for EXAS moved out of overbought territory on February 25, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 55 cases where EXAS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
EXAS broke above its upper Bollinger Band on March 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on March 11, 2026. You may want to consider a long position or call options on EXAS as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXAS advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 235 cases where EXAS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.237) is normal, around the industry mean (11.917). P/E Ratio (0.000) is within average values for comparable stocks, (104.260). EXAS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.679). EXAS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (6.017) is also within normal values, averaging (12.882).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EXAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary technologies for the detection of cancer
Industry MedicalSpecialties
Advertisement